Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telomir Pharmaceuticals, Inc. ( (TELO) ) has issued an update.
On April 22, 2026, Telomir Pharmaceuticals, Inc. completed its previously approved acquisition of TELI Pharmaceuticals, Inc., issuing 34,389,710 restricted common shares to former TELI shareholders based on independently derived valuations. The deal, endorsed by Telomir shareholders on March 23, 2026, was structured under securities law exemptions and included a $1 million contribution at closing from TELI shareholder Bayshore Trust.
Bayshore Trust also agreed to an additional option to invest up to $4 million tied to future milestones, including FDA acceptance of an Investigational New Drug application for Telomir-1 and the start of a Phase 1/2 clinical trial. The acquisition consolidates all global rights to Telomir-1 under Telomir Pharmaceuticals, eliminating prior geographic fragmentation and giving the company unified control over development and potential commercialization in key international markets.
The most recent analyst rating on (TELO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a biotechnology company focused on the development of Telomir-1 (also known as Telomir-Zn), a therapeutic platform with rights spanning major international markets. The company operates in the pharmaceutical and life sciences sector, concentrating on advancing Telomir-1 through regulatory milestones and clinical development toward potential commercialization.
Average Trading Volume: 103,665
Technical Sentiment Signal: Sell
Current Market Cap: $47.45M
See more data about TELO stock on TipRanks’ Stock Analysis page.